any correlation between serum and interstitial fluid samples within the patient samples. Results: Luminex array profiling of the dermal blister fluid showed increased inflammatory cytokines (mean IL-6 in SSc-77.2 pg/ml, HC-17.8 pg/ml, P ¼ 0.009, mean IL-17 in SSc-0.61 pg/ml, HC-0 pg/ml, P ¼ 0.03),and vascular growth factors (VEGF21.7 pg/ml in SSc, HC-13.5 pg/ml (P ¼ 0.26), PDGF-aa 16.4 pg/ml in SSc, HC-0.97 pg/ml, P ¼ 0.049). Additionally MCP-3(CCL7), IL-15 and IFN-g were all significantly increased in SSc compared with HC (P < 0.05). Within the serum, Luminex array profiling highlighted a significant increase in mean IL-12p40 (SSc-31.7 pg/ml, HC-2.05 pg/ml, P ¼ 0.012) and mean IL-1a (SSc-21.15 pg/ml, HC-2.25 pg/ml, P ¼ 0.029) in SSc compared with controls. There was no significant difference for other cytokines. Comparing the luminex array profiling of the dermal blister fluid from those with SSc, with the paired serum samples, the only significant correlation was in MCP-3 (r 2 ¼ 0.31, P ¼ 0.013). Other proinflammatory cytokines [IL-6 (r 2 ¼ 0.083, P ¼ 0.23), IL-17 (r 2 ¼ 0.02, P ¼ 0.56)] and growth factors [VEGF (r 2 ¼ 0.03, P ¼ 0.47), PDGF (r 2 ¼ 0.08, P ¼ 0.22)] showed no correlation between serum samples and dermal blister fluid. Interestingly, the healthy controls showed greater correlation between the Luminex array results from the dermal blister fluid and serum samples, with many reaching significance (IL-10, MCP-3, IL1ra, FGF-2). Conclusion: Our results confirm the potential utility of dermal blister fluid to define local biological processes in SSc, and identifies profibrotic, angiogenic and T-cell derived factors expressed locally within the skin lesions. In contrast, analysis plasma samples revealed elevation of monocyte derived inflammatory proteins. Absence of correlation between the interstitial fluid samples and paired serum samples suggests that the dermal blister sampling method reflects local dermal protein expression rather than exudates from the plasma into the skin. This dermal suction method offers an opportunity to profile the local inflammatory process occurring within the skin and has potential to complement clinical and gene expression based classification to facilitate targeted therapy, as well as providing potential markers of disease activity or treatment effect.
Background: Scleroderma renal pathology is predominantly vascular and fibrotic without major inflammatory features when compared with other autoimmune rheumatic diseases. Accelerated hypertension and rapidly progressive renal dysfunction are hallmarks of scleroderma renal crisis. No current animal model of scleroderma (SSc) develops this complication. The TbRIIÁk-fib transgenic mouse model of SSc has a systemic vascular phenotype comprising hypertension and large vessel adventitial fibrosis without constitutive renal disease. However, the response to long-term further elevation of blood pressure or an inflammatory or toxic renal insult has not been studied. We have therefore explored the link between altered TGFb bioactivity, vasospasm and inflammatory stress on the systemic vascular endothelium using 3 renal injury models: nitric oxide synthase inhibition; nephrotoxic nephritis and ciclosporin toxicity in this strain. Methods: Histological assessment of cardiac and renal architecture, immunostaining for inflammatory cells and assessment of murine serum and urine were performed on adult male transgenic (TG) and littermate wildtype (WT) animals (n ¼ 6) treated with either the NO synthase inhibitor L-NAME for 20 weeks, a single dose of nephrotoxic serum with pre-immunization or ciclosporin 30 mg/kg/day for 4 weeks. Biochemical analysis of the TGFb signalling pathway was performed assessing RNA and protein using whole organ isolates, and by immunostaining of tissue sections. Results were compared with appropriate TG and WT control groups. Results: Increased cardiac mass and collagen measured by both qPCR and Sircol assay in TG and WT treated groups demonstrated that L-NAME treatment successfully induced hypertensive stress in this strain. Whole kidney lysates from L-NAME treated TG animals showed upregulated expression of Col1a1 (TG untreated copy number 3937 AE 315, TG treated 6319 AE 48, P < 0.05) and Pai-1 (TG untreated 410 AE 57, TG treated 740 AE 74, P < 0.05), and glomerulosclerosis was present on sirius red staining in the TG treated group, suggesting that these animals exhibited an enhanced renal fibrotic response when compared with WT treated animals. No other structural vascular changes were identified. In contrast, by day 14, TG animals had developed significantly less proteinuria following treatment with nephrotoxic serum (NTS) when compared with WT littermates (WT 31.8 AE 5 mg/ml, TG 17.8 AE 0.6, P < 0.01. Histological examination showed glomerular damage in both WT and TG animals treated with NTS, with increased severity and number of damaged glomeruli in WT treated mice compared with TG. Following ciclosporin administration, histological and biochemical analyses suggested that TG mice were protected from this injury model. Conclusion: This mouse model demonstrates an exaggerated fibrotic response to hypertensive injury and is relatively resistant to experimental GN and ciclosporin-induced injury. This is likely to be a consequence of increased tissue levels of TGFb. Both of these processes may underpin the unique vascular pathology seen in scleroderma renal crisis, this mouse strain provides a platform for further studies of renal injury in SSc. Disclosure statement: The authors have declared no conflicts of interest.
NAIL-FOLD CAPILLAROSCOPY ABNORMALITIES IN AN UNSELECTED COHORT OF PATIENTS WITH RAYNAUD'S PHENOMENON CONFIRMS SIGNIFICANT ASSOCIATION OF ANTIBODY POSITIVITY AND SSC PATTERNS: EXPERIENCE FROM A SINGLE TERTIARY CENTRE
Lesley-Anne Bissell 1,2 , Giuseppina Abignano 1,2 , Francesco Del Galdo 1,2 and Maya H. Buch 1,2 1 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, 2 NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK Background: Nail-fold capillaroscopy (NFC) patterns of vasculopathy have been well described in SSc but few studies have reported abnormalities in an unselected cohort of patients with RP/across the rheumatic conditions in a real-life clinical setting. Our objectives were to report NFC findings in patients with RP and describe the association with clinical diagnosis and serological profile. Methods: We evaluated patients with primary and secondary RP (pRP or sRP respectively) attending the Leeds Teaching Hospitals NHS Trust rheumatology clinics that were referred for and underwent light/ video-NFC. Prospective documentation included clinical diagnosis, antibody (Ab) status and capillaroscopy findings. Patients were categorized: Ab negative (-ve) pRP, Ab positive (þve) sRP, SScrelated sRP and other CTD-related (non-SSc) sRP. NFC patterns were determined: normal, non-specific, early, active or late SSc patterns. Results: 347 patients were referred to the NFC service between January 2009 and October 2013. Of these, 293 were determined to have true RP (241 (82%) female and mean (S.D.) age 48 (15) years). 193 (66%) were Abþve. 190 (65%) were ANAþve (49 (26%) ACAþve, 11 (6%) Scl70þve and 21 (11%) RNPþve). 79 (27%) had Ab-ve pRP, 99 (34%) Abþve sRP, 49 (17%) SSc-related sRP (4 Ab-ve), and 66 (23%) other (non-SSc) CTD-related sRP (17 Ab-ve). Of the latter, 35 (53%) had UCTD, 14 (21%) inflammatory arthritis, 6 (9%) MCTD, 4 (6%) SLE and 6 (9%) other autoimmune conditions. 11 with sRP had history of digital ulceration (DU). Non-specific abnormalities, and to a lesser extent early patterns, were seen across all diagnoses (Table 1) . Analysing those with sRP, greater active and late patterns were seen in SSc-related sRP than in those without SSc (Abþve sRP or CTDrelated (non-SSc) sRP) (active: 39% vs 7% respectively, relative risk 313 Background: SSc is systemic CTDs, which is characterized by autoimmune disorders, disorders in microcirculation, inflammation and fibrosis of tissues and organs. It was proved that in pathogenesis of SSc are involved many cytokines, including IL-6. The aim of the study was to find association between concentration of IL-6 and the presence of pulmonary disorders confirmed in high resolution computer tomography (HRCT), which may be active (alveolitis) and inactive (without alveolitis), including type of the disease, the presence of markers of inflammation and abnormalities in serological parameters in patients with SSc. Methods: The study was performer in 66 patients with SSc (age 21-74 years), diagnosed on the basis of ARA criteria. Patients were divided into two groups according to the type of the disease: with limited (lSSc) and diffuse skin involvement (dSSc). There were 30 healthy volunteers in the control group. In both groups were determined concentrations of IL-6 using R&D Sytems tests. In patients with SSc were also performed ESR, CRP, fibrinogen, immunoglobulins of IgG, IgM and IgA classes, ANA, Scl-70, ACA and HRCT. Results: As the abnormal values of IL-6 were considered concentrations > 2.5 pg/ml. We found significant difference in IL-6 concentrations between patients with SSc and the control group (P < 0.0007). The analysis within the patients group showed significantly higher concentrations of IL-6 in dSSc in comparison with lSSc (P < 0.0344). The comparison between patients with both active and inactive disorders in lung and patients without pulmonary changes showed increased risk of interstitial lung disease development in patients with high concentration of IL-6 (OR 4.73; 95% CI: 1.28, 17.52). The risk of alveolitis development was the greatest (OR 5.42; 95% CI: 1.22, 23.97). There was also association between high concentration of IL-6 and CRP (OR 4.66; 95% CI: 1.24, 17.45). We found no association with the rest of analysed inflammatory markers and autoantibodies. Conclusion: There is significant association between high concentration of IL-6 and pulmonary disorders in the course of SSc. IL-6 as a proinflammatory factor might be early marker of ILD development in patients with SSc. The median time from SSc onset to HPN was 113 months (range 14-389). All had small intestinal involvement. 80% had proven bacterial overgrowth. 44% had experienced at least one episode of pseudoobstruction. 16% had a small intestinal resection. Prior to HPN initiation, 6 patients failed a naso-enteric feeding trial. 10 patients had a gastrostomy or jejunostomy inserted; 7 of whom received enteral feeding for less than 1 year. The remaining 9 patients commenced HPN directly, without enteral tube feeding, because of the severity of their dysmotility/associated co-morbidity. Only 2 patients were weaned off HPN (after 8 and 29 months) following successful medical optimization. After 1 year, median BMI rose from 18.5 to 21.3. 3 patients received HPN for more than 10 years. The cumulative survivals on HPN after 1, 5 and 10 years were 75%, 37% and 23% respectively. No patients died from HPN-related complications. 16 died from causes related to their SSc. 1 died from malignancy. 8 patients survive, 7 of whom remain on HPN (median duration: 40 months, range 9-178). 9 patients were trained to manage their central venous catheters and self-administer HPN. 16 patients relied on others for their HPN administration. Reported catheter complications included non-thrombotic occlusion (0.70/1000 catheter days), sepsis (0.19/1000 catheter days) and central venous thrombosis (0.11/1000 catheter days). The sepsis rate for all HPN patients, at the same IF centre, is 0.39/1000 catheter days. No one developed IF-associated liver disease.
